drug · small molecule
emraclidine
Phase 2updated 6mo agoby $ABBV AbbVie Inc.🔗 ChEMBL
Phase 2community read0 votes
Small molecule drug with a maximum clinical stage of Phase 2 (across all indications), with 3 investigational indications.
all catalysts(0)
nothing on the calendar yet
Trials studying emraclidine
- phase1Study to Assess Adverse Events and How Oral Emraclidine Moves Through the Body of Adult Healthy Volunteers
- phase2A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
- phase1A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants
- phase2A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
- phase2A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
- phase1A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease
- phase1A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function
- phase1A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine
News(4)
- Neurosterix nabs $105M, recruits Karuna veterans for schizophrenia pushAddex Therapeutics spinout Neurosterix will use the series B funds to advance an oral drug targeting M4, a muscarinic receptor also targeted by BMS’ Cobenfy, which introduced a new mechanism for tr…biospace · 4d ago
- With an approval apiece, the verdict is still out on AbbVie’s and BMS’ twin neuro buysAfter emraclidine’s schizophrenia fail and Cobenfy’s laggard launch, it’s too early to know who made the better buy: AbbVie, in its $8.7 billion Cerevel takeover in late 2023, or Bristol Myers Squi…biospace · 8d ago
- AbbVie wins FDA approval for Parkinson’s drug from $8.7B Cerevel takeoverIn the Phase 3 TEMPO program, AbbVie’s Juvmo elicited significant improvements in motor symptoms and prolonged periods with good symptom control.biospace · 1mo ago
- As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the doorDespite the recent emergence of a new drug class, schizophrenia remains one of the most challenging neuropsychiatric diseases to treat—and Cobenfy's first steps into the market indicate there is st…biospace · 3mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that